Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Cervical Cancer
When would you offer extra-fascial hysterectomy to patients with low-risk early-stage cervical cancer in light of data from the ConCerv trial?
ConCerv trial: Schmeler et al., PMID 34493587
Answer from: at Academic Institution
Stage 1A1 and 2
Sign in or Register to read more
17401
Related Questions
How would you manage a female in her 40s with stage III cervical cancer with hydronephrosis and Crohn's disease?
In patients getting concurrent chemo-immunotherapy for locally advanced cervix cancer, would you hold immunotherapy during the 2.5-3 weeks of brachytherapy?
How would you utilize brachytherapy boost in addition to EBRT for HPV-dependent invasive squamous cell carcinoma present as a large pelvic side wall mass, presumed to be of cervix primary, albeit the negative biopsies of the cervix?
In the context of the ConCerv and SHAPE trials, how would you approach a patient with endometrioid adenocarcinoma within an excised 1.2 cm cervical polyp (negative for LVSI) who has no suspicious lymph nodes on CT scan?
How would you manage bulky cervical adenocarcinoma that incompletely responded to primary chemoradiation?
How long would you continue Bevacizumab and Pembrolizumab after completing 6 cycles of quad therapy (Carbo/ Taxol/ Bev/ Pembro) in a patient with metastatic cervical carcinoma with no evidence of disease (CR) on imaging?
Now that the INTERLACE trial is published, do you plan to do induction chemotherapy prior to chemoRT or chemoRT with immunotherapy (per KEYNOTE-A18) for locally advanced cervical cancer?
What post-treatment surveillance strategy do you employ for patients who undergo conservative fertility-sparing surgery for early-stage cervical cancer?
Would you offer post operative radiation for a patient who had findings of lymphovascular invasion on salvage resection of a recurrent obturator node after definitive chemoradiation for cervical cancer?
Would you ever consider pelvic exenteration followed by SBRT for a patient with recurrent cervical cancer (s/p chemoRT) who has disease only in the central pelvis and in a single hilar lymph node?